糖尿病与闭环之外的人工智能:综述领域格局、前景与挑战
本综述跳出以1型糖尿病闭环系统为中心的视角,系统梳理人工智能与数据驱动系统在各类糖尿病中的应用,涵盖患者教育与自我管理、临床决策支持与预测分析、多模态数据利用;讨论获益与潜在危害证据,以及数据可得与交换、健康不平等、临床医生犹豫和监管等推广障碍。
要点
- 综述覆盖所有糖尿病类型,不限于1型糖尿病的血糖传感器、胰岛素泵与闭环系统。
- 应用领域包括患者教育与自我管理、临床决策支持与预测分析、多模态数据如影像与遗传数据。
- 推广障碍涉及数据可得与交换、健康不平等、临床医生犹豫及监管,需多方协同合作。
核心结论
- 数据与人工智能驱动系统有望在未来数年改变糖尿病照护并融入日常临床实践。
- 利益相关方须主动协作以实现人工智能支持照护的潜在获益,同时降低风险并应对沿途挑战。
研究设计与样本
- 综述,概述人工智能技术并探讨人工智能与数据驱动系统在广泛背景下的应用,覆盖所有糖尿病类型。
主要发现
- 已发表文献与新兴市场产品显示数据与人工智能的更广泛应用在提升临床照护、卫生服务效率与成本效益方面具有前景。
- 综述涵盖三大领域:患者教育与自我管理;临床决策支持系统与预测分析(含诊断支持、治疗与筛查建议、并发症预测);影像或遗传数据等多模态数据的利用。
- 综述讨论了获益与潜在危害的证据,并考虑推广障碍,包括数据可得与交换、健康不平等、临床医生犹豫和监管相关挑战。
临床怎么用
- 综述提出临床医生、学术人员、委托方、政策制定者及有亲历经验者等利益相关方应主动协作,以实现人工智能支持糖尿病照护的潜在获益并降低风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The discourse amongst diabetes specialists and academics regarding technology and artificial intelligence (AI) typically centres around the 10% of people with diabetes who have type 1 diabetes, focusing on glucose sensors, insulin pumps and, increasingly, closed-loop systems. This focus is reflected in conference topics, strategy documents, technology appraisals and funding streams. What is often overlooked is the wider application of data and AI, as demonstrated through published literature and emerging marketplace products, that offers promising avenues for enhanced clinical care, health-service efficiency and cost-effectiveness. This review provides an overview of AI techniques and explores the use and potential of AI and data-driven systems in a broad context, covering all diabetes types, encompassing: (1) patient education and self-management; (2) clinical decision support systems and predictive analytics, including diagnostic support, treatment and screening advice, complications prediction; and (3) the use of multimodal data, such as imaging or genetic data. The review provides a perspective on how data- and AI-driven systems could transform diabetes care in the coming years and how they could be integrated into daily clinical practice. We discuss evidence for benefits and potential harms, and consider existing barriers to scalable adoption, including challenges related to data availability and exchange, health inequality, clinician hesitancy and regulation. Stakeholders, including clinicians, academics, commissioners, policymakers and those with lived experience, must proactively collaborate to realise the potential benefits that AI-supported diabetes care could bring, whilst mitigating risk and navigating the challenges along the way.
引用
- Mackenzie SC, Sainsbury CAR, Wake DJ, et al. Diabetes and artificial intelligence beyond the closed loop: a review of the landscape, promise and challenges. Diabetologia. 2023. PMID: 37979006. doi:10.1007/s00125-023-06038-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。